Publication | Closed Access

Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations

ThrombosisIschemic StrokeCardiovascular DiseaseMedicineCerebrovascular DiseasePlatelet AntagonistAnticoagulantPharmacotherapyNeurologyGenotype-guided Antiplatelet TherapyCost EffectivenessCerebral Blood FlowCyp2c19 LossStrokePublic HealthAtherosclerosisIschemic Syndrome